PAI-1 in Diabetes: Pathophysiology and Role as a Therapeutic Target

Hypofibrinolysis is a key abnormality in diabetes and contributes to the adverse vascular outcome in this population. Plasminogen activator inhibitor (PAI)-1 is an important regulator of the fibrinolytic process and levels of this antifibrinolytic protein are elevated in diabetes and insulin resista...

Descripción completa

Detalles Bibliográficos
Autores principales: Altalhi, Rawan, Pechlivani, Nikoletta, Ajjan, Ramzi A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003717/
https://www.ncbi.nlm.nih.gov/pubmed/33804680
http://dx.doi.org/10.3390/ijms22063170

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003717/
https://www.ncbi.nlm.nih.gov/pubmed/33804680
http://dx.doi.org/10.3390/ijms22063170

Ejemplares similares